Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition.

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803 Akira Inoue,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

The Feasibility Study of Carboplatin Plus Etoposide for Advanced Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias Yuji Minegishi, MD, Hidehiko.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Electronic Updates for JTO Readers

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Phase I/II Study of Docetaxel/Cisplatin/Fluorouracil Combination Chemotherapy Against Metastatic Esophageal Squamous Cell Carcinoma Hiroaki Takahashi,

Standard Outcome Measures for Thymic Malignancies

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

George Blumenschein, MD, John V. Heymach, MD, PhD

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study Cesare Gridelli, MD,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study Seiji Niho,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non- small Cell Lung Cancer: A Retrospective Multicenter Study Wen-Chien.

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy Sophie Papa, MRCP, PhD, Sanjay Popat, FRCP,

Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non– Small-Cell Lung Cancer Grace K. Dy, MD, Paul N. Bogner, MD, Wei Tan,

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell.

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non- small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama.

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,

Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor– Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Debby P. M. van den Bogaert, MD, Ellen M

Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer:

Presentation transcript:

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed Naruo Yoshimura, MD, PhD, Kyoichi Okishio, MD, PhD, Shigeki Mitsuoka, MD, PhD, Tatsuo Kimura, MD, PhD, Tomoya Kawaguchi, MD, PhD, Masaji Kobayashi, MD, PhD, Tomonori Hirashima, MD, PhD, Haruko Daga, MD, PhD, Koji Takeda, MD, PhD, Kazuto Hirata, MD, PhD, Shinzoh Kudoh, MD, PhD Journal of Thoracic Oncology Volume 8, Issue 1, Pages 96-101 (January 2013) DOI: 10.1097/JTO.0b013e3182762bfb Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, Kaplan–Meier estimate of PFS for all patients. The median PFS was 7.0 months (95% CI, 6.2–7.8 months). The 6-month and 1-year progression-free rates were 56.5% and 19.4%, respectively. B, Kaplan–Meier estimate of OS for all patients. The MST was 11.4 months (95% CI, 9.4–13.5 months). The 6-month and 1-year OS rates were 75.5% and 50.0%, respectively. The symbols (I) represent censored patients. PFS, progression-free survival; OS, overall survival; MST, median survival time; CI, confidence interval. Journal of Thoracic Oncology 2013 8, 96-101DOI: (10.1097/JTO.0b013e3182762bfb) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions